AF
LBRX

Allworth Financial’s LB Pharmaceuticals LBRX Stock Holding History

Allworth Financial’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Buy
+1
New +$23 ﹤0.01% 5119

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Allworth Financial's LBRX Position: Q1 2026 in Review

Allworth Financial opened a new position in LB Pharmaceuticals (LBRX) in Q1 2026: 1 share worth $25. The stake represents ﹤0.01% of the portfolio and ranks #5119 among its holdings.

77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Allworth Financial held 1 share of LB Pharmaceuticals worth $25 as of Q1 2026.
  • LB Pharmaceuticals was a new Allworth Financial position in Q1 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #5119 holding.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.